Exact Mass: 367.0726

Exact Mass Matches: 367.0726

Found 34 metabolites which its exact mass value is equals to given mass value 367.0726, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

Pantoprazole sulfide

6-(difluoromethoxy)-2-{[(3,4-dimethoxypyridin-2-yl)methyl]sulfanyl}-1H-1,3-benzodiazole

C16H15F2N3O3S (367.0802)


   

Glutathione bicarbonate

2-[(2-{[4-amino-5-(carboxyperoxy)-1-hydroxy-5-oxopentylidene]amino}-1-hydroxy-3-sulphanylpropylidene)amino]acetic acid

C11H17N3O9S (367.0685)


   

Reminyl

6H-BENZOFURO(3A,3,2-EF)(2)BENZAZEPIN-6-OL, 4A,5,9,10,11,12-HEXAHYDRO-3-METHOXY-11-METHYL-, HYDROBROMIDE, (4A.ALPHA.,6.BETA.,8AR*)-

C17H21NO3.HBr (367.0783)


Galantamine Hydrobromide is the hydrobromide salt form of galantamine, a tertiary alkaloid obtained synthetically or naturally from the bulbs and flowers of Narcissus and several other genera of the Amaryllidaceae family with anticholinesterase and neurocognitive-enhancing activities. Galantamine competitively and reversibly inhibits acetylcholinesterase, thereby increasing the concentration and enhancing the action of acetylcholine (Ach). In addition, galantamine is a ligand for nicotinic acetylcholine receptors, which may increase the presynaptic release of Ach and activate postsynaptic receptors. This agent may improve neurocognitive function in mild and moderate Alzheimer s disease and may reduce abstinence-induced cognitive symptoms that promote smoking relapse. A benzazepine derived from norbelladine. It is found in GALANTHUS and other AMARYLLIDACEAE. It is a cholinesterase inhibitor that has been used to reverse the muscular effects of GALLAMINE TRIETHIODIDE and TUBOCURARINE and has been studied as a treatment for ALZHEIMER DISEASE and other central nervous system disorders. See also: Galantamine (has active moiety). Galanthamine hydrobromide (Galantamine hydrobromide) is a selective, reversible, competitive, alkaloid AChE inhibitor, with an IC50 of 0.35 μM. Galanthamine hydrobromide is a potent allosteric potentiating ligand (APL) of human α3β4, α4β2, α6β4 nicotinic receptors ( nAChRs). Galanthamine hydrobromide is developed for the research of Alzheimer's disease (AD)[1][2][3]. Galanthamine hydrobromide (Galantamine hydrobromide) is a selective, reversible, competitive, alkaloid AChE inhibitor, with an IC50 of 0.35 μM. Galanthamine hydrobromide is a potent allosteric potentiating ligand (APL) of human α3β4, α4β2, α6β4 nicotinic receptors ( nAChRs). Galanthamine hydrobromide is developed for the research of Alzheimer's disease (AD)[1][2][3]. Galanthamine hydrobromide (Galantamine hydrobromide) is a selective, reversible, competitive, alkaloid AChE inhibitor, with an IC50 of 0.35 μM. Galanthamine hydrobromide is a potent allosteric potentiating ligand (APL) of human α3β4, α4β2, α6β4 nicotinic receptors ( nAChRs). Galanthamine hydrobromide is developed for the research of Alzheimer's disease (AD)[1][2][3].

   

Ekatetrone

Ekatetrone

C19H13NO7 (367.0692)


An organic heterotetracyclic compound that is 1,8-dihydroxy-9,10-anthraquinone which is substituted at position 2 and 3 by 3-amino-1-hydroxy-3-oxopropyl and carboxymethyl groups, respectively, in which the hydroxy group beta- to the carboxamide has undergone formal condensation with the carboxy group to give the corresponding delta-lactone. Isolated from various strains of Kitasatospora aureofaciens (Streptomyces aureofaciens), it inhibits the growth of Ehrlich ascites carcinoma in vitro.

   
   
   
   

Galanthamine hydrobromide from Lycoris sp.

Galanthamine hydrobromide from Lycoris sp.

C17H22BrNO3 (367.0783)


   

coptichic aldehyde

coptichic aldehyde

C19H13NO7 (367.0692)


   

Pantoprazole sulfide

5-(Difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl]thio]-1H-benzimidazole

C16H15F2N3O3S (367.0802)


   

Reminyl

6H-BENZOFURO(3A,3,2-EF)(2)BENZAZEPIN-6-OL, 4A,5,9,10,11,12-HEXAHYDRO-3-METHOXY-11-METHYL-, HYDROBROMIDE, (4A.ALPHA.,6.BETA.,8AR*)-

C17H22BrNO3 (367.0783)


Galantamine Hydrobromide is the hydrobromide salt form of galantamine, a tertiary alkaloid obtained synthetically or naturally from the bulbs and flowers of Narcissus and several other genera of the Amaryllidaceae family with anticholinesterase and neurocognitive-enhancing activities. Galantamine competitively and reversibly inhibits acetylcholinesterase, thereby increasing the concentration and enhancing the action of acetylcholine (Ach). In addition, galantamine is a ligand for nicotinic acetylcholine receptors, which may increase the presynaptic release of Ach and activate postsynaptic receptors. This agent may improve neurocognitive function in mild and moderate Alzheimer s disease and may reduce abstinence-induced cognitive symptoms that promote smoking relapse. A benzazepine derived from norbelladine. It is found in GALANTHUS and other AMARYLLIDACEAE. It is a cholinesterase inhibitor that has been used to reverse the muscular effects of GALLAMINE TRIETHIODIDE and TUBOCURARINE and has been studied as a treatment for ALZHEIMER DISEASE and other central nervous system disorders. See also: Galantamine (has active moiety). Galanthamine hydrobromide (Galantamine hydrobromide) is a selective, reversible, competitive, alkaloid AChE inhibitor, with an IC50 of 0.35 μM. Galanthamine hydrobromide is a potent allosteric potentiating ligand (APL) of human α3β4, α4β2, α6β4 nicotinic receptors ( nAChRs). Galanthamine hydrobromide is developed for the research of Alzheimer's disease (AD)[1][2][3]. Galanthamine hydrobromide (Galantamine hydrobromide) is a selective, reversible, competitive, alkaloid AChE inhibitor, with an IC50 of 0.35 μM. Galanthamine hydrobromide is a potent allosteric potentiating ligand (APL) of human α3β4, α4β2, α6β4 nicotinic receptors ( nAChRs). Galanthamine hydrobromide is developed for the research of Alzheimer's disease (AD)[1][2][3]. Galanthamine hydrobromide (Galantamine hydrobromide) is a selective, reversible, competitive, alkaloid AChE inhibitor, with an IC50 of 0.35 μM. Galanthamine hydrobromide is a potent allosteric potentiating ligand (APL) of human α3β4, α4β2, α6β4 nicotinic receptors ( nAChRs). Galanthamine hydrobromide is developed for the research of Alzheimer's disease (AD)[1][2][3].

   

Galanthamine hydrobromide

Galanthamine hydrobromide

C17H22BrNO3 (367.0783)


   

Isosorbide 5-mononitrate glucuronide

Isosorbide 5-mononitrate glucuronide

C12H17NO12 (367.0751)


   

Isosorbide 2-mononitrate glucuronide

Isosorbide 2-mononitrate glucuronide

C12H17NO12 (367.0751)


   

4-(3-Chloro-4-Methoxy-benzylaMino) -2-Methylsulfanyl-pyriMidine-5-carboxylic acid ethyl ester

4-(3-Chloro-4-Methoxy-benzylaMino) -2-Methylsulfanyl-pyriMidine-5-carboxylic acid ethyl ester

C16H18ClN3O3S (367.0757)


   

1,4-Dioxino[2,3-g]quinoline-8-carboxylicacid, 10-chloro-3-(ethoxymethyl)-2,3,6,9-tetrahydro-9-oxo-, ethyl ester

1,4-Dioxino[2,3-g]quinoline-8-carboxylicacid, 10-chloro-3-(ethoxymethyl)-2,3,6,9-tetrahydro-9-oxo-, ethyl ester

C17H18ClNO6 (367.0823)


   

11-Piperazinodibenzo[b,f][1,4]thiazepine dihydrochloride

11-Piperazinodibenzo[b,f][1,4]thiazepine dihydrochloride

C17H19Cl2N3S (367.0677)


   

1-Boc-4-(4-Bromobenzoyl)piperidine

1-Boc-4-(4-Bromobenzoyl)piperidine

C17H22BrNO3 (367.0783)


   

TERT-BUTYL 5-BROMO-2H-SPIRO[BENZOFURAN-3,4-PIPERIDINE]-1-CARBOXYLATE

TERT-BUTYL 5-BROMO-2H-SPIRO[BENZOFURAN-3,4-PIPERIDINE]-1-CARBOXYLATE

C17H22BrNO3 (367.0783)


   

1-Oxa-7-azaspiro[3.5]nonane-7-carboxylic acid, 2-(iodomethyl)-, 1,1-dimethylethyl ester

1-Oxa-7-azaspiro[3.5]nonane-7-carboxylic acid, 2-(iodomethyl)-, 1,1-dimethylethyl ester

C13H22INO3 (367.0644)


   

5-(α-cyclopropylcarbonyl-2-fluorobenzyl)-2-oxo-2,4,5,6,7,7a-hexahydro thieno[3,2-c] pyridine hydrochloride

5-(α-cyclopropylcarbonyl-2-fluorobenzyl)-2-oxo-2,4,5,6,7,7a-hexahydro thieno[3,2-c] pyridine hydrochloride

C18H19ClFNO2S (367.0809)


   

(-)-alpha-(4-Chlorophenyl)benzylamine (+)-tartrate salt

(-)-alpha-(4-Chlorophenyl)benzylamine (+)-tartrate salt

C17H18ClNO6 (367.0823)


   

2,3,4,5-tetramethylcyclopentadienedimethylsilyl-tert-butylamido titanium dichloride

2,3,4,5-tetramethylcyclopentadienedimethylsilyl-tert-butylamido titanium dichloride

C15H27Cl2NSiTi (367.0769)


   

5-(4-cyanophenoxy)-3-[3-(trifluoromethyl)phenyl]-1,2,4-triazine-6-carbonitrile

5-(4-cyanophenoxy)-3-[3-(trifluoromethyl)phenyl]-1,2,4-triazine-6-carbonitrile

C18H8F3N5O (367.0681)


   

Galantamine Hydrobromide Racemic (15 mg)

Galantamine Hydrobromide Racemic (15 mg)

C17H22BrNO3 (367.0783)


   

Copper;imidazol-3-ide;dihydrate

Copper;imidazol-3-ide;dihydrate

C12H16CuN8O2-4 (367.0692)


   

Galantamine Hydrobromide

Galanthamine hydrobromide

C17H22BrNO3 (367.0783)


D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D010277 - Parasympathomimetics D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D002800 - Cholinesterase Inhibitors D002491 - Central Nervous System Agents > D018697 - Nootropic Agents C471 - Enzyme Inhibitor > C47792 - Acetylcholinesterase Inhibitor D004791 - Enzyme Inhibitors Galanthamine hydrobromide (Galantamine hydrobromide) is a selective, reversible, competitive, alkaloid AChE inhibitor, with an IC50 of 0.35 μM. Galanthamine hydrobromide is a potent allosteric potentiating ligand (APL) of human α3β4, α4β2, α6β4 nicotinic receptors ( nAChRs). Galanthamine hydrobromide is developed for the research of Alzheimer's disease (AD)[1][2][3]. Galanthamine hydrobromide (Galantamine hydrobromide) is a selective, reversible, competitive, alkaloid AChE inhibitor, with an IC50 of 0.35 μM. Galanthamine hydrobromide is a potent allosteric potentiating ligand (APL) of human α3β4, α4β2, α6β4 nicotinic receptors ( nAChRs). Galanthamine hydrobromide is developed for the research of Alzheimer's disease (AD)[1][2][3]. Galanthamine hydrobromide (Galantamine hydrobromide) is a selective, reversible, competitive, alkaloid AChE inhibitor, with an IC50 of 0.35 μM. Galanthamine hydrobromide is a potent allosteric potentiating ligand (APL) of human α3β4, α4β2, α6β4 nicotinic receptors ( nAChRs). Galanthamine hydrobromide is developed for the research of Alzheimer's disease (AD)[1][2][3].

   

[4,5-Dihydroxy-10-oxo-3-(3-oxobutanoyl)-9,10-dihydroanthracen-2-yl]acetate

[4,5-Dihydroxy-10-oxo-3-(3-oxobutanoyl)-9,10-dihydroanthracen-2-yl]acetate

C20H15O7- (367.0818)


   

(1S,17S)-7,9-dihydroxy-17-methyl-5,12-dioxo-16,21-dioxapentacyclo[15.3.1.02,15.04,13.06,11]henicosa-2(15),3,6(11),7,9,13-hexaen-3-olate

(1S,17S)-7,9-dihydroxy-17-methyl-5,12-dioxo-16,21-dioxapentacyclo[15.3.1.02,15.04,13.06,11]henicosa-2(15),3,6(11),7,9,13-hexaen-3-olate

C20H15O7- (367.0818)


   

N-(4-fluorophenyl)-2-[(2-methyl-4-benzofuro[3,2-d]pyrimidinyl)thio]acetamide

N-(4-fluorophenyl)-2-[(2-methyl-4-benzofuro[3,2-d]pyrimidinyl)thio]acetamide

C19H14FN3O2S (367.0791)


   

12-deoxynogalonate(1-)

12-deoxynogalonate(1-)

C20H15O7 (367.0818)


An oxo monocarboxylic acid anion that is the conjugate base of 12-deoxynogalonic acid, obtained by deprotonation of the carboxy group. It is the major microspecies at pH 7.3 (according to Marvin v 6.2.0.).

   

2-[(1r)-10,12-dihydroxy-3,6,11-trioxo-1,4-dihydro-2-oxatetracen-1-yl]ethanimidic acid

2-[(1r)-10,12-dihydroxy-3,6,11-trioxo-1,4-dihydro-2-oxatetracen-1-yl]ethanimidic acid

C19H13NO7 (367.0692)


   

2-[(1s)-10,12-dihydroxy-3,6,11-trioxo-1,4-dihydro-2-oxatetracen-1-yl]ethanimidic acid

2-[(1s)-10,12-dihydroxy-3,6,11-trioxo-1,4-dihydro-2-oxatetracen-1-yl]ethanimidic acid

C19H13NO7 (367.0692)


   

2-(10,12-dihydroxy-3,6,11-trioxo-1,4-dihydro-2-oxatetracen-1-yl)ethanimidic acid

2-(10,12-dihydroxy-3,6,11-trioxo-1,4-dihydro-2-oxatetracen-1-yl)ethanimidic acid

C19H13NO7 (367.0692)